Loading patent…
AssigneesCristalia Produtos Quimicos Farmaceuticos Ltda., Genpharma Consultoria Farmaceutica E Genetica Ltda.
InventorsKrishnamurti De Morais Carvalho, Dòris Maria Fernandes Carvalho, Maria Denise Fernandes Carvalho, Ogari de Castro Pacheco, Roberto Carlos Debom Moreira
Estimating the term…
The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.
A method for treating acute or chronic pain, comprising administering, to a human being or animal in need of said treatment, an effective amount of telocinobufagin, or an enantiomer or prodrug thereof that is selected from the group consisting of carbonates, carbamates, phosphates, phosphonates, glycosides, sulfates, fulfonates, ethers and esters of telocinobufagin, optionally in combination with a pharmaceutically acceptable excipient, wherein the pain is acute neurogenic pain or chronic neuropathic pain.
Dependencies are inferred from the claim text.